MBD2 is a critical component of a methyl cytosine–binding protein complex isolated from primary erythroid cells

Evan P. Kransdorf, Shou Zhen Wang, Sheng Zu Zhu, Timothy B. Langston, Jeremy W. Rupon, and Gordon D. Ginder

The chicken embryonic β-type globin gene, ρ, is a member of a small group of vertebrate genes whose developmentally regulated expression is mediated by DNA methylation. Previously, we have shown that a methyl cytosine–binding complex binds to the methylated ρ-globin gene in vitro. We have now chromatographically purified and characterized this complex from adult chicken primary erythroid cells. Four components of the MeCP1 transcriptional repression complex were identified: MBD2, RBAP48, HDAC2, and MTA1. These 4 proteins, as well as the zinc-finger protein p66 and the chromatin remodeling factor MI2, were found to coelute by gel-filtration analysis and pull-down assays. We conclude that these 6 proteins are components of the MeCPC. In adult erythrocytes, significant enrichment for MBD2 is seen at the inactive ρ-globin gene by chromatin immunoprecipitation assay, whereas no enrichment is observed at the active βA-globin gene, demonstrating MBD2 binds to the methylated and transcriptionally silent ρ-globin gene in vivo. Knock-down of MBD2 resulted in up-regulation of a methylated ρ-gene construct in mouse erythroleukemic (MEL)–ρ cells. These results represent the first purification of a MeCP1-like complex from a primary cell source and provide support for a role for MBD2 in developmental gene regulation. (Blood. 2006;108:2836-2845)

Introduction

Methylation of the 5-position of cytosine residues in DNA has an important role in the regulation of gene expression in higher eukaryotes. The first descriptions of an inverse correlation between DNA methylation and expression of a protein-coding eukaryotic gene were those made for the vertebrate globin genes of the chicken, rabbit, and human.1,2,3 The tremendous interest in DNA methylation seen within the past decade stems from its important role in the silencing of tumor suppressor genes in cancer.4-6 Despite the prediction of a widespread role for DNA methylation in gene regulation,7 the expression of only a small number of vertebrate genes has been shown to be tissue-restricted or developmentally restricted by DNA methylation.8 Studies showing tissue-restricted or developmentally restricted expression in nontransformed, primary cells are even more scarce and are limited to 4 main examples: the Gallus gallus ρ-globin gene,9,10 the Mus musculus interleukin-4 and interferon-γ genes,11 and the Xenopus laevis mesodermal genes.12

Intense study has been directed toward elucidating the mechanisms through which DNA methylation represses transcription. The discovery of a family of proteins that specifically recognize methylated DNA, the methyl-CpG-binding proteins (MCBPs),13,14 has led to the general observation of these proteins and their associated corepressor complexes as the mediators of DNA methylation-induced gene silencing in a variety of systems.15-19 Biochemical studies have shown that the MCBPs are members of distinct and nonoverlapping transcriptional repression complexes. MBD1 was identified as a critical component of an S phase–specific complex that propagates the DNA methylation signal into a dimethylation of lysine 9 of histone H3 (H3-K9-Me2) signal during DNA replication.17 MBD2 is the methyl-CpG-binding component of the MeCP1 transcriptional repression complex.20 MBD3 is a core component of the NuRD transcriptional repression complex that can be recruited by DNA-binding proteins such as Ikaros and FOG1.21,22 Kaiso has been found to be a component of the N-CoR transcriptional repression complex.23 The embryonic-to-adult β-globin switch in the chicken serves as an informative model of transcriptional silencing. The ρ-globin gene is expressed abundantly in primitive erythrocytes produced in the yolk sac from 36 hours of embryogenesis to day 5, and it is not expressed in the definitive erythrocytes which are produced beginning at day 5.24 The definitive cells do not express ρ-globin because of transcriptional silencing.25 Work in our laboratory has established that every CpG site in the promoter and proximal transcribed region (exon 1 and intron 1) of the ρ-globin gene is methylated in adult erythrocytes but unmethylated in primitive erythrocytes.10,26,27 This observation is functionally significant, because expression of ρ-globin and a concomitant loss of CpG methylation can be induced in adult chickens by treatment with the DNA methylation inhibitor 5-aza-cytidine.9

From the Massey Cancer Center, the Department of Internal Medicine, the Department of Microbiology and Immunology, the Department of Human Genetics, and the Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond.


Supported by the National Institutes of Health (grant DK29902) and by institutional funding from the Massey Cancer Center.

E.P.K. designed and performed the research, analyzed the data, and wrote the paper; S.Z.W., S.Z.Z., and T.B.L. performed the research and analyzed the data; J.W.R. contributed reagents; and G.D.G. designed the research and wrote the paper.

The online version of this article contains a data supplement.

Reprints: Gordon D. Ginder, Departments of Internal Medicine, Human Genetics, and Microbiology and Immunology, Massey Cancer Center, Virginia Commonwealth University, 401 College St, PO Box 980037, Richmond, VA 23298-0037; e-mail: ggdginder@vcu.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.
Our laboratory has also shown that an erythroid methyl cytosine–binding protein complex (MeCPC) forms on the methylated α-globin promoter and proximal transcribed region (p-PTR) when incubated with chicken erythroid nuclear extracts in vitro. This complex exhibits a 2-fold binding preference for the p-PTR over the canonical MeCPC binding substrate M-CG1, in contrast to a 20-fold binding preference exhibited by the MeCPC complex for M-CG11 over the p-PTR. In an effort to understand the mechanistic basis for DNA methylation-mediated transcriptional silencing of the p-globin gene during normal development in the chicken, we purified the MeCPC from primary erythroid cells and show that it contains 6 components of the MeCPC1 complex. Importantly, we find that the chicken homolog of MBD2 is a component of the MeCPC and is bound to the methylated p-globin gene in primary adult erythrocytes. cMBD2 associates with the other components of the MeCPC complex in vivo, and the MeCPC components MBD2 and MTA2 are present at the methylated p-globin gene in mouse erythroleukemic (MEL) cells containing a methylated p-globin mini-locus. This study therefore presents the first evidence of a direct association of a MeCPC1-type complex with a gene regulated by DNA methylation during the course of normal development.

Methods and materials

Additional details and methods are described in Document S1 (available at the Blood website; see the Supplemental Materials link at the top of the online article). All enzymes were from New England Biolabs (Beverly, MA), and all chromatography columns were from Amersham Biosciences (Piscataway, NJ) unless otherwise noted.

Expression and purification of recombinant cMBD2
EST clone pat . p k0057 . c7 . f was obtained from the UD Chick EST Database28 and sequenced. This sequence has been deposited in GenBank as accession no. AY888006. The insert, encoding chicken MBD2, was amplified by polymerase chain reaction (PCR) and cloned into the vector pGEX-6P. This plasmid was introduced into Rosetta (Millipore, Bedford, MA), and all chromatography columns were from Amersham Biosciences (Piscataway, NJ) unless otherwise noted.

Anti-cMBD2 IgG purification and affinity purification

Purification of the antigen derived from the 2 immunized rabbits (V1 and V2) was performed using a 5-mL HiTrap rProtein A FF column according to the manufacturer’s recommendations. Protein containing fractions were pooled and dialyzed against PBS overnight. For affinity purification, purified GST/cMBD2 was bound to 0.4 mL Affi-Gel 10 (Bio-Rad, Hercules, CA) by the manufacturer’s protocol. After equilibration with PBS, V1 IgG was passed over the column 4 times. The column was then washed with 15 CV PBS, and then the bound antibodies were eluted with 5 CV 0.1 M glycine (pH 2.8). The antibody-containing fractions were concentrated by spinning with the use of an Ultrafree-4 (Millipore, Bedford, MA).

Electrophoretic mobility shift assay
DNA fragments were methylated as previously described27 and labeled with [α-32P]dCTP (MP Biomedicals, Solon, OH) and Klenow or [γ-32P]ATP and polynucleotide kinase. The assay was performed by adding 4 to 10 μL column fractions or 20 μg nuclear extract to a 21.5-μL binding reaction containing 10 to 20 fmol probe, 2 μg sonicated M lysodeikitos DNA, 20 mM HEPES (pH 7.9), 3 mM MgCl2, 1 mM EDTA, 10 mM β-ME, 0.1% Triton X-100, 4% glycerol. Binding reactions were incubated on ice for 20 minutes and then loaded onto a 2% agarose gel and resolved in 0.5 × TBE buffer. Supershift experiments were performed as previously described27 by using protein A-purified anti-cMBD2 antibodies or anti-mMBD2 antibodies (no. 07-198; Upstate, Charlottesville, VA).

Isolation of chicken erythrocytes and preparation of nuclear extracts
Whole chicken blood was obtained from Pel-Freez Biologicals (Rogers, AR). Erythrocytes were isolated by centrifugation on a 8:3 (vol:vol) cushion of Histopaque 1083 (Sigma, St Louis, MO) by spinning at 3100g for 5 minutes. Nuclear extracts were prepared using the method of Dignam et al.29

Purification of the MeCPC by strategies I and II
Detailed methods are described in Document S1. In strategy I, adult chicken red blood cell (RBC) nuclear extract was desalted using a HiPrep Desalting 16/20 column and loaded onto a 20-mL DEAE Sepharose FF column. The eluted fractions were desalted and injected onto a UnoQ6 column (Bio-Rad). Bound protein was eluted and injected to a Superose 6 10/30 column. Fractions 8 through 13 were concentrated and injected onto a 1-mL HiTrap Heparin Sepharose HP column. Purification strategy II was similar to purification strategy I except for the insertion of a SP Sepharose column step after the initial DEAE column and omission of the Heparin Sepharose HP column. Methods used for protein electrophoresis, mass spectrometry, and peptide mass fingerprint data analysis are described in Document S1.

Bird system and pull-down assays
The cDNA for BirA was subcloned from pGEM-SD2-BirA (kind gift of John Strouboulis, Erasmus University Medical Center, Rotterdam, The Netherlands) by digestion with EcoRI/SpeI followed by incubation with Klenow. This blunt-ended fragment was ligated into pTarget (Promega, Madison, WI) that had been cut with EcoRI and incubated with Klenow. A cDNA encoding the 23 amino acid BirA acceptor peptide (BAP) (BAP) was commercially synthesized (Blue Heron Biotechnology, Bothell, WA) and cloned into the NheI and EcoRI sites of pTracer/CMV-Bsd (Invitrogen, Carlsbad, CA) to create pTracer/BAP. The cDNA for cMBD2 was amplified using Platinum Pfimer polymerase (Invitrogen) and cloned into the EcoRI and EcoRV sites of pTracer/BAP to create BAP-cMBD2. 6C2 cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Pull-down assays were performed as described,30 except that the beads were washed 6 times with wash buffer containing NaCl (200 mM × 1, 400 mM × 2, 600 mM × 2, 50 mM × 1). Methods used for protein electrophoresis and mass spectrometry are described in detail in Document S1.

Chromatin immunoprecipitation assay
RBCs were collected from 5-day or 18-day chicken embryos and purified by Histopaque as above, washed twice with Leibovitz medium, and crosslinked with formaldehyde (0.5% final). MEL cells were crosslinked in culture medium with formaldehyde (1.0% final). Crosslinking was quenched after 10 minutes with 125 mM glycine. Cells were washed twice with PBS and resuspended in cell lysis buffer31 and incubated on ice for 10 minutes. The resulting nuclei were collected by centrifugation at 850g for 2 minutes and resuspended in nuclei lysis buffer31 without sodium butyrate and incubated on ice for 10 minutes. After supplementation with glass beads, the lysate was sonicated (model W-220F; Misonix, Reamstown, PA).

From www.bloodjournal.org by guest on September 7, 2017. For personal use only.
Derivation of MEL-α cells and RNAi

The p-globin mini-focus was assembled as described\(^{32}\) and cloned into the vector pCDNA4/TO/delP using Pmel. A 2.5-kb (kilobase) fragment of the p-globin gene extending from 248 bp (base pair) upstream to 2.2 kb downstream of the cap site was excised from the vector by digesting with BstBI and NotI, methylated in vitro with SsoI methylase and religated. The ligation reaction was digested with ScaI and run on an agarose gel. The correctly ligated target product runs on the gel as a 13-kb linear band. The band was excised, and then the DNA was recovered by digestion with GELase (Epigenetix Biotechnologies, Madison, WI). MEL cells were transfected by Lipofectamine 2000 (Invitrogen). MEL-α cells were selected with zeocin (Invitrogen) at 500 μg/mL and dilution-cloned. Methods used for knock-down of MBD2 by RNAi can be found in Document S1.

Antibodies, Western blotting, cell culture, and mouse splenocytes

Anti-MENT antibodies were the kind gift of Sergei Grigoryev (Penn State College of Medicine, State College, PA). Anti-RBAP48, anti-HDAC2, anti-p66, and anti-MI2 antibodies were from Upstate (catalog nos. 05-524, 07-222, 07-365, 06-878). Anti-MTA1 antibodies were from Peter O’Connell (Virginia Commonwealth University School of Medicine, Richmond, VA). Anti-MTA2 antibodies were from Santa Cruz Biotechnology (sc-944T).

Western blotting was performed as described previously.\(^{27}\) 6C2 cells were grown as described.\(^{33}\) MEL cells were grown as described previously.\(^{27}\) Splencytes were prepared by first removing spleens from MBD2 wild-type and MBD2\(^{-/-}\) mice (kind gift of Adrian Bird, University of Edinburgh, Edinburgh, Scotland), and cells were prepared by the method of Kazazian et al.\(^{34}\) The protocol for obtaining mouse tissues was approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee.

Results

Data from our earlier electrophoretic mobility shift assay (EMSA) supershift experiments suggested that MBD2 is a component of the MeCPC.\(^{27}\) In addition to confirming this finding, we sought to identify and characterize the chicken homolog of MBD2 (cMBD2). At the initiation of these studies, the genomic data resources for the chicken were limited to 2 expressed sequence tag (EST) libraries. Both libraries were searched in silico with the cDNA sequence of mouse MBD2 (mMBD2). We identified an EST sequence, present in both libraries, that was highly similar to mMBD2. The corresponding EST clone was obtained, and the insert was sequenced. The clone encoded an open reading frame of 257 amino acids that was 83% identical at the amino acid level to the short or “B” isoform of human and mouse MBD2 (Figure S1).\(^{13}\) Because of the high degree of sequence similarity between the mammalian and chicken proteins and conservation of amino acid residues known to be required for binding of the MBD to the methyl-CpG,\(^{35}\) this protein was thought likely to be the chicken homolog of MBD2.

To determine whether cMBD2 has methyl-CpG-binding activity in vitro, a recombinant GST/cMBD2 fusion protein was produced for use in gel-shift assays. A 50-bp subfragment of the p-globin gene MeCP complex substrate containing a single CpG (a1CpG) was the parent sequence used as a probe in the gel-shift assays. This sequence was mutated to create additional probes containing 0 (a0CpG), 2 (a2CpG), or 3 CpGs (a3CpG). The sequences of these probes are listed in Figure 1A. The probes were methylated in vitro, end-labeled, then incubated with and without GST/cMBD2 and subjected to EMSA. As can be seen in Figure 1B, GST/cMBD2 binds to the probes containing 1, 2, and 3 methyl-CpGs but not to the mock-methylated probe containing 0 methyl-CpGs. Thus, cMBD2 is a bona fide MCBP and can bind to DNA fragments containing as few as 1 methyl-CpG. This finding is consistent with the results obtained by Fraga et al.\(^{39}\) for recombinant mouse MBD2.

For further characterization of cMBD2, polyclonal antibodies were generated by immunizing 2 rabbits with GST/cMBD2. Both anti-cMBD2 antibodies (named V1 and V2) recognized an endogenous protein of 28 kDa in multiple chicken cell types, including primary erythroid cells (see Figure S2). Using the anti-cMBD2 antibodies, we wanted to establish that cMBD2 was a component of the MeCPC complex we observed by EMSA. "Supershift" experiments were performed by adding the V1 or V2 antibodies to the EMSA binding reactions. The addition of V2 antibodies, but not control IgG, retarded the mobility of the MeCPC complex (supershift) during EMSA.

To understand the binding preference of the MeCPC for the methylated p-PTR over the canonical MeCP1 binding substrate M-CG11, we sought to determine what the protein components of the complex are, in particular any factors that may be unique to the MeCPC as compared with the MeCP1 complex derived from HeLa cells.\(^{20}\) We developed a chromatography scheme to purify the complex from primary chicken erythroid cell nuclear extracts composed of 4 column steps (Figure 2A). The fractions from the final column of the purification scheme displayed intact MeCPC binding activity in fractions 32 through 36 (Figure 2B), indicating that the complex was stable during purification. The purified sample was run on a 10% SDS-PAGE gel, and the proteins in the sample less than 85 kDa were identified by MALDI-TOF followed by peptide mass fingerprinting (PMF). The SDS-PAGE gel of the final MeCPC sample is shown in Figure 2C (left) with the match for each gel band indicated in Figure 2C (right). Using a novel algorithm that fits PMF data to EST contigs within the ChickEST
The proteins cMBD2, RBAP48, HDAC2, and MTA1 were identified in the purified MeCPC sample. Given that these 4 proteins were previously identified as components of the MeCP1 complex, they were considered putative components of the MeCPC. We identified 4 additional proteins: eIF3i, eIF3h, eIF3e, and HSPC021. Five additional proteins were identified: β-actin, MENT, p50unk, BAF60b, and FMIP. Neither the eIF3 complex, FMIP, nor p50unk has been shown to have a role in transcriptional repression or chromatin modulation; therefore, it is likely that these proteins were contaminants in the purified MeCPC sample.

Although β-actin and BAF60b are components of mammalian SWI/SNF-type chromatin remodeling complexes and β-actin in particular has been shown to have an important role in transcription, we did not further investigate this complex because of our failure to identify any other components of this complex (such as BAF53). However, the functional properties of MENT suggested that it might be associated with the MeCPC. MENT is a member of the serine-protease inhibitor family that has been found to be sufficient for higher-order chromatin folding and nucleosome compaction. It has also been shown to possess DNA-binding and chromatin-modulating activity. Because MENT is abundantly expressed in terminally differentiated hematopoietic cells such as erythrocytes, we hypothesized that MENT could be a component of the MeCPC and could contribute to the binding preference of the complex.

We repeated the purification of the MeCPC by using a modified scheme (Figure 3A), in which the Superose 6 gel-filtration column was the final step in the procedure. The fractions from the Superose 6 column displayed intact MeCPC binding activity that eluted in fractions 8 through 15, in a molecular weight range of 2000 to 667 kDa (Figure 3B). In addition, a slower-migrating supercomplex elutes in fractions 10 through 13 and a faster-migrating subcomplex elutes in fractions 18 and 19. Both the MeCPC and supercomplex fail to retard an unmethylated β-globin probe, whereas the subcomplex is able to form on an unmethylated substrate (Figure 3C). The origin of the supercomplex remains unknown. However, the appearance of the lower molecular weight subcomplex in fractions 18 and 19 coincides with the presence of undersized immunoreactive bands by Western blotting for the MeCPC component proteins Mi2 and p66 (data not shown). Thus, we hypothesize that the subcomplex results from cleavage of MeCPC component proteins during biochemical purification.

Western blotting was performed on the Superose 6 fractions with antibodies against several of the proteins identified by mass spectrometry as well as the other known components of the MeCP1 complex. Western blots with antibodies against cMBD2, HDAC2, p56, MTA1, and Mi2 show a strikingly similar profile (Figure 3D) that matches the elution profile of the MeCPC activity. Western blotting with antibodies against MENT showed that this protein coeluted with the MeCP1 factors, suggesting that this abundantly expressed protein was not a contaminant in the purified MeCPC fractions. Western blotting with antibodies against RBAP48 showed that this protein also coeluted with the MeCP1 factors, although it elutes over a larger set of fractions. This may be because RBAP48 is a component of multiple transcriptional repression complexes, such as the Sin3A and the Rb complexes.

To confirm the biochemical interaction of cMBD2 with the other components of the MeCP1 complex identified in the Superose 6 fractions, we performed pull-down assays using the BirA biotin-tagging system. First, we generated BirA+ stable transfectants in the avian pre-erythroid cell line 6C2. Next, a cMBD2 expression construct with an N-terminal biotin acceptor peptide (BAP) was introduced into the cells. Expression of cMBD2 was similar in BirA- and BirA+ 6C2 cells containing BAP-cMBD2;
however, biotinylation of cMBD2 was only seen in BirA\textsuperscript{+} cells (Figure 4A). Pull-down assays were then performed by binding nuclear extracts from BirA\textsuperscript{−} and BirA\textsuperscript{+} BAP-cMBD2 6C2 cells to streptavidin beads. We identified the 5 major components of the MeCP1 complex in the eluate from BirA\textsuperscript{+} cells, whereas no components were identified in the eluate from BirA\textsuperscript{−} cells (Figure 4B). Interestingly, MENT was not found in the eluate, indicating that this protein does not directly interact with MBD2 in vivo. To further delineate the interaction partners of cMBD2, the eluate from cMBD2 pull-down assays was analyzed by mass spectrometry. Analysis of major bands again revealed the 5 major components of the MeCP1 complex (Figure 4C). Given the chromatographic and affinity copurification of cMBD2, RBAP48, HDAC2, p66, MTA2, and Mii2, we conclude that these 6 factors are components of the MeCPC in chicken erythroid cells.

The identification of MBD2 as a component of the MeCPC supports a role for this protein in the transcriptional repression of the p-globin gene in adult chicken red blood cells. To determine whether MBD2 is associated with the methylated p-globin gene in vivo, ChIP assays were performed using affinity purified anti-cMBD2 antibodies in embryonic day 5 and adult erythrocytes. Antibodies against trimethylated lysine 4 of histone H3 (H3-K4-Me\textsubscript{3}), a marker of active transcription in chicken erythrocytes,\textsuperscript{48} were used as a control. The amount of p-globin or \(\beta^A\)-globin DNA in the total DNA immunoprecipitated with each antibody was determined by quantitative PCR. At the p-globin gene, no enrichment for cMBD2 is seen in embryonic day 5 erythrocytes in which the gene is transcriptionally active and highly enriched for H3-K4-Me\textsubscript{3} (Figure 5A). In contrast, in adult erythrocytes significant enrichment for cMBD2 is seen at the transcriptionally inactive and methylated p-globin gene that is depleted of H3-K4-Me\textsubscript{3}-modified chromatin. The ChIP assay therefore establishes that cMBD2 binds to the transcriptionally inactive p-globin gene in adult chicken erythroid cells in vivo.

The expression and methylation pattern of the \(\beta^A\)-globin gene is opposite that of the p-globin gene: it is transcriptionally active in adult erythrocytes and transcriptionally inactive and methylated in primitive erythrocytes.\textsuperscript{26} The observed pattern of cMBD2 and H3-K4-Me\textsubscript{3} enrichment around the \(\beta^A\)-globin gene

![Figure 3](image3.png)  
**Figure 3.** Putative components of the MeCPC copurify from a Superose 6 gel-filtration column. (A) The second chromatographic scheme (strategy II) was used to purify the MeCPC from primary erythroid cells. The fractions eluted from each column were assayed for MeCPC activity by EMSA using the methylated M-p248 probe. (B) EMSA on the high molecular weight fractions from the final column of MeCPC purification strategy II (Superose 6) using the methylated M-p248 probe. The MeCPC elutes primarily in fractions 8 through 15 in a molecular weight range of 670 to 2000 kDa. The position of the MeCPC is indicated as “M.” The slower-migrating supercomplex as “Sup.” Although the exact composition of the supercomplex is unknown, we hypothesize that the subcomplex results from cleavage of MeCPC component proteins during biochemical purification. (C) EMSA on the high molecular weight fractions from the final column of MeCPC purification strategy II (Superose 6) using the unmethylated p248 probe. Both the MeCPC and the supercomplex fail to retard the mobility of an unmethylated probe. In contrast, the subcomplex is able to retard the p248 probe (fractions 18 and 19). (D) Western blot analysis of the high molecular weight fractions from the Superose 6 gel-filtration column. The antibody used for each blot is determined by quantitative PCR. At the...
enriched at the transcriptionally inactive and methylated erythrocytes. In contrast, H3-K4-Me 3 is enriched at the transcriptionally active erythrocytes. In contrast, H3-K4-Me 3 is depleted. In contrast, no enrichment is observed in embryonic day 5 erythrocytes in which H3-K4-Me 3 is strongly enriched. Once again, H3-K4-Me 3 is depleted from the transcriptionally active β^A^-globin gene in adult erythrocytes. No enrichment was seen using anti-rabbit IgG in either 5-day or adult erythrocytes, verifying the interaction of these specific proteins with the β^A^-globin gene. The data represent the average of 3 independent experiments, with the SD indicated by the bar. (B) Enrichment for MBD2, H3-K4-Me 3, and IgG at the β^A^-globin gene in 5-day (□) and adult (■) erythrocytes as determined by ChIP assay. The data show that MBD2 is depleted from the transcriptionally active β^A^-globin gene in 5-day erythrocytes but enriched at the transcriptionally inactive and methylated β^A^-globin gene in adult erythrocytes. In contrast, H3-K4-Me 3 is enriched at the transcriptionally active β^A^-globin gene and depleted at the transcriptionally inactive gene. No enrichment was seen using anti–rabbit IgG in either 5-day or adult erythrocytes, verifying the interaction of these specific proteins with the β^A^-globin gene. The data represent the average of 3 independent experiments, with the SD indicated by the bar.

Given that cMBD2 binds to the methylated β^-globin gene and is able to pull-down the other major components of the MeCPC in vivo, it is an attractive target for clinical therapies aimed at alleviating methylation-mediated transcriptional silencing by disrupting the effector complexes of methylation. We made use of the MBD2-knockout mouse to assess whether MBD2 is required for formation of the MeCPC in vivo. Primary splenic erythroblasts were isolated from both MBD2^+/+ and MBD2^−/− mice rendered anemic to convert the spleen to a primarily erythropoietic organ. Erythroblasts were subjected to nuclear extract preparation. As can be seen in Figure 6B, the MeCPC is present in primary erythroblasts from MBD2^+/+ animals and MBD2 is a component of the complex, as indicated by supershift of the MeCPC band by the inclusion of anti-mMBD2 antibodies but not control IgG. In contrast, no MeCPC activity is detectable in primary splenic erythroblasts from MBD2^−/− animals, indicating that MBD2 is essential for formation of the MeCPC.

Next, we assessed the necessity of MBD2 for transcriptional repression of the methylated β^-globin gene by knocking-down mMBD2 by RNAi in the MEL-β^-globin gene by knocking-down mMBD2 by RNAi in the MEL-β^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the MELβ^-globin gene by knocking-down mMBD2 by RNAi in the
of repression seen with methylated \(\beta\)-globin gene constructs transfected into primary avian erythrocytes.

**Discussion**

In this study we have characterized the chicken homolog of MBD2 and found that an erythroid methyl cytosine–binding protein complex isolated from primary erythroid cells contains cMBD2 as well as the other major components of the MeCP1 complex: RBAP48, HDAC2, p66, MTA2, and Mi2. Given that the \(\beta\)-globin gene is methylated during development and that a methylated probe corresponding to a segment of the \(\beta\)-globin gene was used to monitor the elution of MeCP activity from each column, it is likely that our biochemical data are highly relevant to the in vivo environment. Indeed, we have verified that cMBD2 binds to the methylated \(\beta\)-globin gene in embryonic day 5 erythrocytes and the methylated \(\beta\)-globin gene in adult erythrocytes. Furthermore, we have shown that MBD2 is required for formation of the MeCPC in primary splenic erythrocytes and that expression of the methylated \(\beta\)-globin gene is increased in MEL-\(\beta\)-cells. Significant knock-down of mMBD2 expression is seen in MEL-\(\beta\)-cells containing shRNA-expressing plasmids that target mMBD2, as compared with control cells (lanes 3 and 4 as compared with lanes 1 and 2). No \(\beta\)-globin expression is seen in MEL-\(\beta\)-cells with wild-type MBD2 expression (lane 2). In contrast, robust \(\beta\)-globin expression is seen in MEL-\(\beta\)-cells in which mMBD2 expression has been knocked down by shRNA (lane 4). Loading of RNA for all MEL samples was equal, as shown by equal amounts of 18S RNA present in the samples. This datum indicates that MBD2 is functionally required for full transcriptional silencing of the methylated \(\beta\)-globin gene. Significant knock-down of mMBD2 expression is seen in all 3 samples, demonstrating equal RNA loading. Chicken genomic DNA was used as a positive control for the \(\beta\)-globin probe.

**Composition of methyl-DNA–binding protein complexes**

Because of their potential fundamental importance in interpreting cytosine methylation to regulate transcription, numerous studies have sought to define the components of methyl cytosine–binding transcriptional complexes. Here, we report the purification of a MeCP1-like complex from primary
erythroid cells. This represents the first purification of such a complex from a primary cell source. Analysis of protein complexes in primary cells serves as an important adjunct to studies of complexes in cultured cells, because biochemical interactions based on transient signals such as protein posttranslational modification or kinase signaling may be lost or artifactually gained over time in culture. Indeed, we observe the formation of a methylation-dependent supercomplex of unknown composition that has not been previously observed during the isolation of MeCP1-like complexes from immortalized cells.

Our analysis of the MeCPC failed to identify cMBD3 as a component, either by mass spectrometry or Western analysis (data not shown). Recent work by Le Guezennecc et al. supports this finding, showing that, indeed, MBD2 and MBD3 form mutually exclusive complexes with NuRD components. We also failed to identify GATA1 or FOG1 as tissue-specific components of the MeCPC, either by mass spectrometry or Western analysis (data not shown). Recent work by Rodriguez et al. found that GATA1 pulled down the complete components of the MeCPC complex, and work by Hong et al. found that FOG1 pulled down the complete components of the NuRD complex. Our failure to identify either of these tissue-restricted factors likely reflects the known heterogeneity of MeCP1- and NuRD-like complexes.

Our chromatographic analysis of the composition of the MeCPC identified MENT as a protein that tightly copurified with the other MeCPC components. However, MENT was not pulled down by biotin-tagged cMBD2 in cultured cell extracts, indicating either that it does not biochemically associate with cMBD2 in vivo or that cultured cells differ from primary cells.

RbAp48, which is known to be a component of multiple protein complexes, is pulled down by biotin-tagged MENT (data not shown). This finding provides an explanation for the observation of MENT in the same Superose 6 fractions that contain the MeCPC. Therefore, we favor the conclusion that MENT is not part of the MeCPC.

Role of MBD2 in developmental gene regulation

Despite numerous reports of genes whose transcription is inversely related to the level of DNA methylation at CpG sites in a specific cell-type and the demonstration of a profound effect of DNA methylation during vertebrate embryonic development, only a limited number of genes have been shown to be developmentally regulated by DNA methylation. A distinct yet important class of genes is that of tumor suppressor genes methylated in cancer cells, whereby the methylation pattern is abnormal (i.e., it differs from that of a nontransformed cell of the same type).

Two particularly well-studied examples of normal developmental regulation by DNA methylation are the avian p-globin gene and the murine interleukin-4 gene. Previously, our laboratory has shown that every CpG within the promoter- and proximal-transcribed region of the p-globin gene is methylated in adult chicken erythroid cells in which the gene is transcriptionally inactive. DNA methylation has also been shown to be involved in the transcriptional silencing of the baboon and human gamma-globin genes. Clinically, erythroid cells of patients receiving treatment of sickle cell disease and beta-thalassemia with the DNA methylation inhibitors 5-aza-cytidine and 5-aza-2'-deoxycytidine have increased transcription of the gamma-globin genes.

Here, we show that MBD2 binds to the methylated and transcriptionally silent p-globin gene in adult erythroid cells, but it does not bind to the same region in embryonic day 5 erythrocyes in which the gene is transcriptionally active. Furthermore, abrogation of MBD2 function is associated with loss of MeCPC formation and derepression of a methylated p-globin gene. The data presented here on the composition of the MeCPC and the role of MBD2 in regulating the chicken p-globin gene are potentially highly relevant to the human beta-globin locus. In support of this, our laboratory has recently determined that the fetal gamma-globin gene is ectopically expressed at high levels in adult RBCs from MBD2−/− mice that contain a single copy human beta-globin locus YAC.

Our data parallel those of Hutchins et al., who found that MBD2 was bound to 2 methylated regions of the interleukin-4 gene in Th0 cells when the gene was transcriptionally inactive but displaced from the same regions when the transcriptional activator GATA-3 was expressed in the cells. Considering the work presented here and that of Hutchins et al. together, a role for MBD2 in developmental gene regulation is emerging. Given that MBD2 is not required for normal mammalian embryonic development and confers a minimally abnormal phenotype, MBD2 may be an excellent target for therapeutic modulation aimed at altering developmental and neoplastic gene expression patterns.

Acknowledgments

We thank Dr. Richard Moran for advice and discussions regarding protein characterization and Catharine Tucker for assistance in the preparation of this manuscript.
References


MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells

Evan P. Kransdorf, Shou Zhen Wang, Sheng Zu Zhu, Timothy B. Langston, Jeremy W. Rupon and Gordon D. Ginder